Black Diamond Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 65

Employees

  • Stock Symbol
  • BDTX

Stock Symbol

  • Share Price
  • $2.57
  • (As of Thursday Closing)

Black Diamond Therapeutics General Information

Description

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-189 and BDTX-1535.

Contact Information

Formerly Known As
Aset Therapeutics, Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • One Main Street, 10th Floor
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Black Diamond Therapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.57 $2.37 $1.22 - $6.85 $133M 51.6M 528K -$2.13

Black Diamond Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 85,251 (49,905) (13,091) 829,275
Revenue 0 0 0 0
EBITDA (85,912) (92,692) (128,855) (71,242)
Net Income (84,112) (91,169) (125,596) (67,254)
Total Assets 172,382 156,255 247,682 329,670
Total Debt 26,042 28,140 28,460 8,741
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Black Diamond Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Black Diamond Therapeutics‘s full profile, request access.

Request a free trial

Black Diamond Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Black Diamond Therapeutics‘s full profile, request access.

Request a free trial

Black Diamond Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development
Biotechnology
Cambridge, MA
65 As of 2022
00000
00000000 00000

000000

tetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magn
0000 000000000
San Diego, CA
000 As of 0000
00000
00000000 00000

000000

re eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sun
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Black Diamond Therapeutics Competitors (49)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000000 000000 Corporate Backed or Acquired Montreal, Canada 0 000000&0
00000000000 000000 Formerly VC-backed Newark, CA 000 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, United Kingdom 000 00000 000000000 00000
You’re viewing 5 of 49 competitors. Get the full list »

Black Diamond Therapeutics Patents

Black Diamond Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022215616-A1 Quinoxaline derivatives and uses thereof Pending 05-Feb-2021 0000000000
CA-3207475-A1 Quinoxaline derivatives and uses thereof Pending 05-Feb-2021 0000000000
AU-2021368798-A9 Method of treating cancers with alkyne substituted quinazoline derivatives Pending 02-Nov-2020 0000000000
AU-2021368798-A1 Method of treating cancers with alkyne substituted quinazoline derivatives Pending 02-Nov-2020 000000000
CA-3195473-A1 Method of treating cancers with alkyne substituted quinazoline derivatives Pending 02-Nov-2020 A61P35/00
To view Black Diamond Therapeutics’s complete patent history, request access »

Black Diamond Therapeutics Executive Team (12)

Name Title Board Seat Contact Info
Mark Velleca Ph.D Chief Executive Officer & Chairman
Fang Ni Chief Business Officer
Brent Hatzis-Schoch JD Chief Operating Officer, Operations & General Counsel, Legal
Melanie Morrison Chief Development Officer
Elizabeth Buck Ph.D Chief Scientific Officer & Founder
You’re viewing 5 of 12 executive team members. Get the full list »

Black Diamond Therapeutics Board Members (13)

Name Representing Role Since
Alexander Mayweg Ph.D Versant Ventures Board Member 000 0000
Ali Behbahani MD New Enterprise Associates Board Member 000 0000
Bradley Bolzon Ph.D Versant Ventures Board Member 000 0000
David Epstein Ph.D Black Diamond Therapeutics Co-Founder, President and Chief Executive Officer 000 0000
Derek DiRocco Ph.D Self Board Observer 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Black Diamond Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Black Diamond Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Black Diamond Therapeutics‘s full profile, request access.

Request a free trial

Black Diamond Therapeutics ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

26.36 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

0.000

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,912

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 965

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 443

Rank

00.00

Percentile

To view Black Diamond Therapeutics’s complete esg history, request access »